Epidermal Growth Factor Receptor Status and Notch Inhibition in Non-small Cell Lung Cancer Cells

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2015 Oct 27

PMID 26497899

Citations 9

Authors

Efstathia Giannopoulou

Achilleas Nikolakopoulos

Dimitra Kotsirilou

Angeliki Lampropoulou

Sofia Raftopoulou

Evangelia Papadimitriou

Achilleas D Theocharis

Thomas Makatsoris

Konstantinos Fasseas

Haralabos P Kalofonos

Affiliations

Soon will be listed here.

Abstract

Background: Notch may behave as an oncogene or a tumor suppressor gene in lung cancer cells. Notch receptor undergoes cleavage by enzymes, including γ-secretase, generating the active Notch intracellular domain (NICD). The aim of the present study was to investigate the effect of DAPT, a γ-secretase inhibitor, in non-small cell lung cancer (NSCLC) cells, as well as the impact of epidermal growth factor (EGF) that is over-expressed by NSCLC cells, on Notch signaling. H23, A549, H661 and HCC827 human NSCLC cell lines were used, expressing various NICD and EGF receptor (EGFR) protein levels.

Results: DAPT decreased the number of H661 cells in a concentration-dependent manner, while it had a small effect on H23 and A549 cells and no effect on HCC827 cells that carry mutated EGFR. Notch inhibition did not affect the stimulatory effect of EGF on cell proliferation, while EGF prevented DAPT-induced NICD decrease in H23 and H661 cells. The type of cell death induced by DAPT seems to depend on the cell type.

Conclusions: Our data indicate that inhibition of Notch cleavage may not affect cell number in the presence of EGFR mutations and that EGFR may affect Notch signalling suggesting that a dual inhibition of these pathways might be promising in NSCLC.

Citing Articles

Preclinical Models for Functional Precision Lung Cancer Research.

Yu J, Kiss Z, Ma W, Liang R, Li T Cancers (Basel). 2025; 17(1.

PMID: 39796653 PMC: 11718887. DOI: 10.3390/cancers17010022.

Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.

Kouhmareh K, Martin E, Finlay D, Bhadada A, Hernandez-Vargas H, Downey F PLoS One. 2024; 19(7):e0306450.

PMID: 39083508 PMC: 11290651. DOI: 10.1371/journal.pone.0306450.

Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study.

Kouhmareh K, Martin E, Finlay D, Bhadada A, Hernandez-Vargas H, Downey F bioRxiv. 2023; .

PMID: 37781582 PMC: 10541091. DOI: 10.1101/2023.09.19.558270.

Magnetic Iron Nanocubes Effectively Capture Epithelial and Mesenchymal Cancer Cells.

Suresh D, Ghoshdastidar S, Gangula A, Mukherjee S, Upendran A, Kannan R ACS Omega. 2020; 5(37):23724-23735.

PMID: 32984691 PMC: 7513327. DOI: 10.1021/acsomega.0c02699.

PTEN inhibits non-small cell lung cancer cell growth by promoting G/G arrest and cell apoptosis.

Liu L, Huang L, He J, Cai S, Weng Y, Huang S Oncol Lett. 2019; 17(1):1333-1340.

PMID: 30655903 PMC: 6313010. DOI: 10.3892/ol.2018.9719.

References

Dai J, Ma D, Zang S, Guo D, Qu X, Ye J . Cross-talk between Notch and EGFR signaling in human breast cancer cells. Cancer Invest. 2009; 27(5):533-40. DOI: 10.1080/07357900802563036. View

Wang Z, Li Y, Ahmad A, Azmi A, Banerjee S, Kong D . Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):258-67. PMC: 2955995. DOI: 10.1016/j.bbcan.2010.06.001. View

DAddario G, Felip E . Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:68-70. DOI: 10.1093/annonc/mdp132. View

Westhoff B, Colaluca I, dArio G, Donzelli M, Tosoni D, Volorio S . Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009; 106(52):22293-8. PMC: 2799768. DOI: 10.1073/pnas.0907781106. View

Doroquez D, Rebay I . Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit Rev Biochem Mol Biol. 2006; 41(6):339-85. DOI: 10.1080/10409230600914344. View

Barth J, Hafen E, Kohler K . The lack of autophagy triggers precocious activation of Notch signaling during Drosophila oogenesis. BMC Dev Biol. 2012; 12:35. PMC: 3564699. DOI: 10.1186/1471-213X-12-35. View

Mazzone M, Selfors L, Albeck J, Overholtzer M, Sale S, Carroll D . Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A. 2010; 107(11):5012-7. PMC: 2841923. DOI: 10.1073/pnas.1000896107. View

Reade C, Ganti A . EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics. 2009; 3:215-24. PMC: 2726075. View

Kang J, Lee E, Park S, Chung I . MUC5AC expression through bidirectional communication of Notch and epidermal growth factor receptor pathways. J Immunol. 2011; 187(1):222-9. DOI: 10.4049/jimmunol.1003606. View

10.

Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y, Mori K . Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncol Rep. 2010; 24(5):1141-6. DOI: 10.3892/or_00000965. View

11.

Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge S . Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol. 2013; 201(2):279-92. PMC: 3628517. DOI: 10.1083/jcb.201209151. View

12.

Mahalingam D, Mita A, Mita M, Nawrocki S, Giles F . Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer. 2009; 33(2):73-111. DOI: 10.1016/j.currproblcancer.2009.03.001. View

13.

Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S . Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol. 2010; 137(5):771-8. DOI: 10.1007/s00432-010-0934-4. View

14.

Wang N, Sanborn Z, Arnett K, Bayston L, Liao W, Proby C . Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011; 108(43):17761-6. PMC: 3203814. DOI: 10.1073/pnas.1114669108. View

15.

Andre F, Le Chevalier T, Soria J . Her2-neu: a target in lung cancer?. Ann Oncol. 2003; 15(1):3-4. DOI: 10.1093/annonc/mdh033. View

16.

Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos H . Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2010; 29(12):5077-82. View

17.

Scagliotti G, Govindan R . Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010; 15(5):436-46. PMC: 3227980. DOI: 10.1634/theoncologist.2009-0225. View

18.

Collins B, Kleeberger W, Ball D . Notch in lung development and lung cancer. Semin Cancer Biol. 2004; 14(5):357-64. DOI: 10.1016/j.semcancer.2004.04.015. View

19.

Adamo V, Franchina T, Adamo B, Denaro N, Gambadauro P, Chiofalo G . Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther. 2009; 8(3):206-12. DOI: 10.4161/cbt.8.3.7465. View

20.

Purow B, Sundaresan T, Burdick M, Kefas B, Comeau L, Hawkinson M . Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis. 2008; 29(5):918-25. PMC: 2902388. DOI: 10.1093/carcin/bgn079. View